Terumo Gestione

Gestione criteri di controllo 1/4

Terumo Il CEO è Hikaru Samejima, nominato in Apr2024, ha un mandato di meno di un anno. possiede direttamente 0.003% delle azioni della società, per un valore di $ 781.60K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.8 anni e 3.1 anni.

Informazioni chiave

Hikaru Samejima

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.003%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	3.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Hikaru Samejima (60 yo)

less than a year

Mandato

Mr. Hikaru Samejima served as Director of Terumo Corporation since February 7, 2024 until June 26, 2024 and serves as its Representative Director since June 26, 2024. He serves as President and CEO of Teru...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Toshiaki Takagi	Chairman of the Board & Group Managing Executive Officer	14.4yrs	JP¥137.00m	Nessun dato
Hikaru Samejima	Representative Director	less than a year	Nessun dato	0.0027% $ 781.6k
Jin Hagimoto	CFO, CIO	less than a year	Nessun dato	Nessun dato
Shinji Omori	CTO, GM of DX Promotion Dept. R&D Division and Executive Officer	less than a year	Nessun dato	Nessun dato
Miho Mizuguchi	Executive Officer	8.6yrs	Nessun dato	Nessun dato
Tomoko Adachi	Chief Human Resources Officer & Group Executive Officer	1.8yrs	Nessun dato	Nessun dato
Kazunori Hirose	Director & Group Managing Executive Officer	no data	Nessun dato	0.0023% $ 664.1k
Itaru Sakaguchi	Group Managing Executive Officer	less than a year	Nessun dato	Nessun dato
Toshihiko Osada	Group Senior Managing Executive Officer & Director	no data	Nessun dato	Nessun dato
Fumihisa Hirose	Group Managing Executive Officer	less than a year	Nessun dato	Nessun dato
Norimasa Kunimoto	Director & Group Managing Executive Officer	1.6yrs	Nessun dato	0.0026% $ 769.8k
Antoinette Gawin	Group Senior Managing Executive Officer	less than a year	Nessun dato	Nessun dato

0.8yrs

Durata media

60.5yo

Età media

Gestione esperta: Il team dirigenziale di TRUM.Y non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Toshiaki Takagi	Chairman of the Board & Group Managing Executive Officer	14.4yrs	JP¥137.00m	Nessun dato
Hikaru Samejima	Representative Director	less than a year	Nessun dato	0.0027% $ 781.6k
Kazunori Hirose	Director & Group Managing Executive Officer	2.8yrs	Nessun dato	0.0023% $ 664.1k
Toshihiko Osada	Group Senior Managing Executive Officer & Director	less than a year	Nessun dato	Nessun dato
Norimasa Kunimoto	Director & Group Managing Executive Officer	1.4yrs	Nessun dato	0.0026% $ 769.8k
Soichiro Uno	Independent Director	5.4yrs	Nessun dato	Nessun dato
Hidenori Nishi	Independent Outside Director	4.4yrs	Nessun dato	0.00029% $ 85.2k
Takanori Shibazaki	Director	3.4yrs	Nessun dato	0.0025% $ 725.8k
Koichi Sakaguchi	Substitute Director	2.4yrs	Nessun dato	Nessun dato
Masaichi Nakamura	Independent Outside Director	5.4yrs	Nessun dato	0.00037% $ 108.7k
Keiya Ozawa	Independent Outside Director	3.4yrs	Nessun dato	0.00011% $ 32.3k
Mari Kogiso	Independent Director	less than a year	Nessun dato	Nessun dato

3.1yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TRUM.Y sono considerati esperti (durata media dell'incarico 3.1 anni).

Terumo Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Recent updates

Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.

Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024

Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System

Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024

Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024

Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023

Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.

Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023

Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023

Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022

Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543).

NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation.

Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.

Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Terumo Corporation Provides Dividend Guidance for the Year Ending March 2022

Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc.

Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd

Terumo Corporation Revises Earnings Guidance for the Fourth Quarter of Fiscal 2021

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

Terumo Corporation to Report Q3, 2021 Results on Feb 04, 2021

Diabeloop SA. and Terumo Corporation Enter into Joint Development Agreement with Exclusive Distribution Right for Dblg1 Automated Insulin Delivery Solution in Japanese Market

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

Terumo Corporation to Report Q2, 2021 Results on Nov 05, 2020

Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc.

Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million.

Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media